FOXP3⁺ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF𝜶 Agents

Table 1

Peripheral blood study: baseline characteristics of patients.

Variable	Results
	𝑁 (%)	Median (range)
White race	32 (100)
Male	17 (53)
Age at entry (yr)		33.5 (14–72)
Crohn’s disease	25 (78)
Disease site
(i) Ileum	7 (28)
(ii) Ileocolon	17 (68)
(iii) Colon	1 (4)
(iv) Perianal disease	5 (18)
Ulcerative colitis	7 (22)
Extension
(i) Left colitis	1 (14)
(ii) Pancolitis	6 (86)
Duration of disease (mo)		36 (6–312)
CDAI at T0	25 (78)	223 (155–330)
CAI at T0	7 (22)	9 (6–16)
CRP at T0 (mg/L)		5.7 (0.17–136)
Previous intestinal resection in CD patients	6 (19)
Medications at baseline
(i) Corticosteroids ± 5-ASA	11 (34)
(ii) Azathioprine ± 5-ASA	9 (28)
(iii) 5-ASA/Sulfasalamine	5 (16)
(iv) None	7 (22)
Medications during anti-TNFα therapy
(i) Corticosteroids	1 (3)
(ii) AZA	21 (66)
(iii) None	10 (31)
Anti-TNFα
(i) Infliximab	22 (69)
(ii) Adalimumab	4 (12)
(iii) Certolizumab pegol	6 (19)

CDAI: Crohn’s disease activity index; CAI: colitis activity index; CRP: C-reactive protein; 5-ASA: 5-aminosalycilic acid; TNF: tumor necrosis factor; AZA: azathioprine.